Physician
Henry Ford Macomb Hospital Corporation
Henry Ford Macomb Hospital Corporation was paid $40.96M by Medicaid between Jan 2018 and Dec 2024, across 325 billing codes. Its largest line is 99285, emergency room visit (most serious) — 30% of everything it billed.
33Billing provider infoHENRY FORD MACOMB HOSPITAL CORPORATION
CLINTON TWP, MI 48038
CLINTON TWP, MI 48038
33aNPI1023114634assigned 09/15/2006
33bProvider typeDiagnostic Radiology Physician
28Total paid$40.96M
24GClaims1,110,332
24DCodes billed325
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Diagnostic Radiology Physician providers in Michigan
Rank by total paid#4 of 139
Median peer was paid$28K
This provider vs. median1,460×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DAMSCHRODER, ROBIN controls 14+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 169,862 | $6.64M | |
| 2019 | 185,293 | $6.36M | |
| 2020 | 155,839 | $5.30M | |
| 2021 | 178,434 | $6.24M | |
| 2022 | 161,116 | $5.88M | |
| 2023 | 149,622 | $5.78M | |
| 2024incomplete | 110,166 | $4.77M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 30% | 38,005 | 35,435 | $12.09M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.8% | 18,288 | 17,469 | $3.19M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.7% | 19,263 | 18,669 | $2.33M |
| G0378 | Hospital observation service, per hour | 5.6% | 7,139 | 6,586 | $2.31M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.0% | 22,047 | 20,469 | $2.05M |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 3.3% | 16,992 | 16,498 | $1.37M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.1% | 24,049 | 19,700 | $1.26M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 42,510 | 11,866 | $985K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 9,242 | 6,669 | $855K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.9% | 7,716 | 7,111 | $794K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 5,725 | 5,617 | $705K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.6% | 9,031 | 8,820 | $663K |
313 more codes
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 1.5% | 10,260 | $610K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.4% | 9,389 | $562K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 16,029 | $519K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 18,219 | $519K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.0% | 2,593 | $429K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 1.0% | 4,495 | $414K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,514 | $366K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 26,356 | $348K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 12,911 | $338K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,021 | $325K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,620 | $301K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,776 | $278K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,588 | $263K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 765 | $259K |
| 93975 | <1% | 2,303 | $251K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 11,611 | $232K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 5,687 | $229K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,995 | $225K |
| 76830 | Ultrasound, transvaginal | <1% | 3,971 | $223K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 451 | $217K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 3,441 | $203K |
| 80061 | Lipid panel | <1% | 7,270 | $200K |
| 70496 | <1% | 1,294 | $191K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,635 | $185K |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 3,355 | $184K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,006 | $183K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,608 | $165K |
| 97161 | <1% | 3,113 | $160K | |
| 59025 | Fetal non-stress test | <1% | 1,993 | $157K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,054 | $139K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,805 | $132K |
| 97162 | <1% | 2,626 | $125K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 644 | $125K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,507 | $114K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 19,574 | $113K |
| 93970 | <1% | 1,138 | $100K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,510 | $95K |
| 76642 | <1% | 2,430 | $94K | |
| 76801 | <1% | 1,692 | $93K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 993 | $90K |
| 93971 | <1% | 1,588 | $84K | |
| 80053 | Comprehensive metabolic panel | <1% | 29,308 | $82K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,811 | $77K |
| 77066 | Tomosynthesis, mammo | <1% | 1,214 | $70K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 60,135 | $66K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,114 | $66K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,244 | $62K |
| 76770 | <1% | 1,060 | $60K | |
| 76536 | <1% | 1,150 | $57K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,209 | $53K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 900 | $52K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 123 | $52K |
| 71250 | <1% | 914 | $51K | |
| 72141 | <1% | 350 | $50K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 825 | $50K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,993 | $50K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,385 | $48K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 181 | $48K |
| 96367 | <1% | 1,414 | $47K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,684 | $46K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,266 | $44K |
| 72100 | <1% | 2,251 | $40K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 211 | $40K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,359 | $39K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 38,096 | $37K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,963 | $37K |
| 86900 | <1% | 7,710 | $36K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 146 | $34K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,850 | $34K |
| 73562 | <1% | 2,875 | $30K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,831 | $30K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 215 | $28K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 281 | $27K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,447 | $26K |
| 73630 | <1% | 3,421 | $26K | |
| 93017 | <1% | 979 | $24K | |
| 73130 | <1% | 2,638 | $24K | |
| 73610 | <1% | 2,861 | $23K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 100 | $23K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,942 | $23K |
| 73030 | <1% | 2,347 | $22K | |
| 82728 | <1% | 3,294 | $22K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 11,456 | $21K |
| 82607 | <1% | 3,073 | $21K | |
| 85027 | <1% | 11,666 | $21K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,232 | $19K |
| 74022 | <1% | 1,896 | $18K | |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 161 | $18K |
| 84702 | <1% | 7,966 | $16K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,596 | $16K |
| 43235 | <1% | 44 | $16K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,932 | $15K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,829 | $14K |
| 74018 | <1% | 1,661 | $14K | |
| 83550 | <1% | 3,088 | $14K | |
| 73110 | <1% | 1,596 | $14K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 38 | $13K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 314 | $13K |
| 73502 | <1% | 1,264 | $12K | |
| 83735 | <1% | 28,022 | $12K | |
| 64450 | <1% | 376 | $12K | |
| 82746 | <1% | 1,784 | $12K | |
| 84439 | <1% | 2,463 | $11K | |
| 97035 | <1% | 1,951 | $11K | |
| 73221 | <1% | 105 | $11K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,376 | $11K |
| 83540 | <1% | 3,327 | $11K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 72 | $10K |
| 85610 | <1% | 22,002 | $10K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 50 | $10K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 301 | $10K |
| 86780 | <1% | 839 | $9K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,229 | $9K |
| 86803 | <1% | 1,144 | $9K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,702 | $9K |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 1,163 | $9K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,085 | $9K |
| 51798 | <1% | 718 | $8K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 31 | $8K |
| 87081 | <1% | 10,552 | $7K | |
| 83880 | <1% | 4,081 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,720 | $7K |
| 71101 | <1% | 400 | $7K | |
| 72050 | <1% | 193 | $7K | |
| 83970 | <1% | 262 | $6K | |
| 71271 | <1% | 113 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,840 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,831 | $6K |
| 97116 | <1% | 665 | $6K | |
| 82565 | <1% | 1,854 | $6K | |
| 82570 | <1% | 2,128 | $6K | |
| 92523 | <1% | 54 | $6K | |
| 82248 | <1% | 16,154 | $5K | |
| 86850 | <1% | 7,656 | $5K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 371 | $5K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 14 | $5K |
| 86140 | <1% | 2,984 | $5K | |
| 85730 | <1% | 19,444 | $5K | |
| 87808 | <1% | 2,115 | $5K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 44 | $5K |
| 96417 | <1% | 130 | $5K | |
| 96415 | <1% | 97 | $5K | |
| 81001 | <1% | 17,450 | $4K | |
| 87631 | <1% | 1,502 | $4K | |
| 70498 | <1% | 1,196 | $4K | |
| 76882 | <1% | 78 | $4K | |
| 29580 | <1% | 45 | $4K | |
| 73080 | <1% | 612 | $4K | |
| 84460 | <1% | 1,452 | $4K | |
| 87340 | <1% | 824 | $4K | |
| 80076 | <1% | 680 | $3K | |
| 72110 | <1% | 93 | $3K | |
| 84450 | <1% | 1,450 | $3K | |
| 86039 | <1% | 597 | $3K | |
| 72040 | <1% | 299 | $3K | |
| 93798 | <1% | 75 | $3K | |
| 84100 | <1% | 3,327 | $3K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 12 | $3K |
| 77080 | <1% | 53 | $3K | |
| 87186 | <1% | 2,507 | $3K | |
| 82043 | <1% | 831 | $3K | |
| 82947 | <1% | 516 | $3K | |
| 87634 | <1% | 873 | $2K | |
| 85007 | <1% | 2,905 | $2K | |
| 87077 | <1% | 1,691 | $2K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 255 | $2K |
| 70491 | <1% | 25 | $2K | |
| 85652 | <1% | 2,238 | $2K | |
| 74019 | <1% | 192 | $2K | |
| 29515 | <1% | 31 | $2K | |
| 73140 | <1% | 450 | $2K | |
| 83615 | <1% | 822 | $2K | |
| 87070 | <1% | 1,295 | $2K | |
| 97166 | <1% | 40 | $2K | |
| 86901 | <1% | 7,709 | $2K | |
| 10060 | <1% | 26 | $2K | |
| 74183 | <1% | 16 | $2K | |
| 73590 | <1% | 400 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 159 | $2K |
| 84156 | <1% | 1,045 | $2K | |
| 88342 | <1% | 667 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,799 | $2K |
| 83690 | <1% | 11,686 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,594 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,974 | $2K |
| 97165 | <1% | 38 | $2K | |
| 82550 | <1% | 1,578 | $2K | |
| 70486 | <1% | 58 | $1K | |
| 97014 | <1% | 160 | $1K | |
| 72114 | <1% | 127 | $1K | |
| 84484 | <1% | 13,438 | $1K | |
| 87205 | <1% | 1,488 | $1K | |
| 84520 | <1% | 649 | $1K | |
| 76881 | <1% | 15 | $993.36 | |
| 94726 | <1% | 14 | $981.07 | |
| 82105 | <1% | 130 | $971.23 | |
| 81003 | <1% | 8,332 | $968.72 | |
| 36591 | <1% | 18 | $966.98 | |
| 86480 | <1% | 26 | $890.25 | |
| 85379 | <1% | 3,235 | $890.22 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 26 | $869.43 |
| 73090 | <1% | 274 | $868.20 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,336 | $856.23 |
| 81025 | <1% | 16,414 | $851.21 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 494 | $781.22 |
| 72170 | <1% | 392 | $691.83 | |
| 87088 | <1% | 796 | $675.77 | |
| 87210 | <1% | 964 | $591.67 | |
| 86706 | <1% | 110 | $562.11 | |
| 86431 | <1% | 163 | $554.56 | |
| 86376 | <1% | 73 | $547.56 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 195 | $525.75 |
| 87430 | <1% | 4,760 | $496.37 | |
| 82951 | <1% | 63 | $451.54 | |
| 84425 | <1% | 37 | $440.09 | |
| 87420 | <1% | 937 | $419.03 | |
| 84403 | <1% | 27 | $392.88 | |
| 85045 | <1% | 306 | $391.26 | |
| 87147 | <1% | 599 | $385.72 | |
| 84550 | <1% | 201 | $375.88 | |
| 80164 | <1% | 121 | $372.08 | |
| 87040 | <1% | 2,268 | $353.38 | |
| 82247 | <1% | 126 | $309.69 | |
| 89060 | <1% | 104 | $305.14 | |
| 82962 | <1% | 9,936 | $292.60 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 13,607 | $290.67 |
| 84481 | <1% | 39 | $279.91 | |
| 88304 | <1% | 593 | $261.59 | |
| 86255 | <1% | 37 | $259.13 | |
| 84480 | <1% | 40 | $251.33 | |
| 72052 | <1% | 12 | $250.98 | |
| 86308 | <1% | 1,217 | $236.73 | |
| 72072 | <1% | 13 | $208.40 | |
| G0168 | Wound closure utilizing tissue adhesive(s) only | <1% | 35 | $202.50 |
| 83605 | <1% | 3,539 | $202.08 | |
| 86762 | <1% | 74 | $187.12 | |
| 86769 | <1% | 12 | $178.56 | |
| 80074 | <1% | 12 | $173.94 | |
| 82077 | <1% | 5,289 | $171.45 | |
| 88307 | <1% | 40 | $139.03 | |
| 96376 | <1% | 6,767 | $131.28 | |
| 86200 | <1% | 14 | $110.49 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,900 | $102.91 |
| 86592 | <1% | 44 | $92.80 | |
| 82952 | <1% | 38 | $91.52 | |
| 82784 | <1% | 12 | $88.66 | |
| 82465 | <1% | 32 | $87.17 | |
| 80178 | <1% | 44 | $85.64 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,131 | $72.54 |
| 85651 | <1% | 57 | $62.03 | |
| 82803 | <1% | 353 | $55.90 | |
| 84165 | <1% | 12 | $55.02 | |
| 73060 | <1% | 12 | $48.48 | |
| J3490 | Unclassified drugs | <1% | 2,297 | $43.98 |
| 84436 | <1% | 27 | $42.95 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,515 | $34.00 |
| 70360 | <1% | 13 | $31.59 | |
| 85014 | <1% | 78 | $29.71 | |
| 80143 | <1% | 3,021 | $27.71 | |
| 84132 | <1% | 64 | $26.20 | |
| 29125 | <1% | 148 | $21.39 | |
| 80179 | <1% | 2,971 | $15.43 | |
| 97803 | <1% | 56 | $12.94 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 567 | $7.37 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 147 | $3.94 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,318 | $3.48 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,036 | $2.30 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 17 | $1.42 |
| C1769 | Guide wire | 0% | 686 | $0.00 |
| 12001 | 0% | 156 | $0.00 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 224 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 152 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 272 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 761 | $0.00 |
| 76870 | 0% | 68 | $0.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 1,482 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 110 | $0.00 |
| 96368 | 0% | 337 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 65 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 98 | $0.00 |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | 0% | 92 | $0.00 |
| Q0247 | Injection, sotrovimab, 500 mg | 0% | 28 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 33 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 63 | $0.00 |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 48 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 56 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 18 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 13 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 739 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 97 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 85 | $0.00 |
| 99152 | 0% | 143 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 747 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 62 | $0.00 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 265 | $0.00 |
| 12011 | 0% | 64 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 203 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 13 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 110 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 229 | $0.00 |
| C1729 | Catheter, drainage | 0% | 48 | $0.00 |
| 90715 | 0% | 181 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 60 | $0.00 |
| L1902 | Ankle orthosis, ankle gauntlet or similar, with or without joints, prefabricated, off-the-shelf | 0% | 26 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 164 | $0.00 |
| C1765 | Adhesion barrier | 0% | 55 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 48 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 151 | $0.00 |
| 94729 | 0% | 14 | $0.00 | |
| 82010 | 0% | 19 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 28 | $0.00 |
| 84145 | 0% | 42 | $0.00 | |
| 77062 | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAMSCHRODER, ROBIN (EXECUTIVE VICE PRESIDENT, FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Henry Ford Health System | Detroit, MI | $334.91M |
| Henry Ford Health ST. John Hospital | Chicago, IL | $159.41M |
| Henry Ford Health Providence Hospital | Novi, MI | $72.76M |
| Henry Ford Wyandotte Hospital | Wyandotte, MI | $60.54M |
| Henry Ford Health Macomb Oakland Hospital | Warren, MI | $59.25M |
| W.A. Foote Memorial Hospital | Jackson, MI | $41.32M |
| Henry Ford Health Genesys Hospital | Grand Blanc, MI | $31.39M |
| Henry Ford Health Macomb Oakland Hospital | Madison Heights, MI | $24.76M |
| Henry Ford Health System | West Bloomfield, MI | $19.27M |
| Henry Ford Health Rochester Hospital | Rochester, MI | $11.98M |
| Henry Ford Health River District Hospital | East China, MI | $4.59M |
| W.A. Foote Memorial Hospital | Jackson, MI | $2.11M |
| Henry Ford Health Providence Hospital | Novi, MI | $255K |
| Henry Ford Health ST. John Hospital | Detroit, MI | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.